Trial Outcomes & Findings for A Study of MK-5720 in Participants With Schizophrenia (MK-5720-001) (NCT NCT05953740)

Results Overview

An adverse event (AE) is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experienced one or more AEs is reported here for participants in Period 1. Per protocol, this outcome measure has been reported by panel and dose. As specified by the protocol, Period 2 has been analyzed separately and reported later in the record.

Recruitment status

COMPLETED

Study phase

PHASE1

Target enrollment

17 participants

Primary outcome timeframe

Up to approximately 10 days

Results posted on

2025-03-04

Participant Flow

Participants with schizophrenia were enrolled. Only participants in Panel A, Panel B, and dose-matched placebo were enrolled. Participants were not enrolled in Panels C, D, E, and F and no data was collected.

Participant milestones

Participant milestones
Measure	Panel A: Period 1 MK-8189 4 mg → Period 2 MK-5720 35mg Participants received 7 days of oral MK-8189 4 mg (Period 1), followed by a single intramuscular (IM) injection of MK-5720 35 mg (Period 2).	Panel B: Period 1 MK-8189 8 mg → Period 2 MK-5720 70 mg Participants received 7 days of oral MK-8189 8 mg (Period 1), followed by a single IM injection of MK-5720 70 mg (Period 2).	Placebo Period 1 → Placebo Period 2 Participants received 7 days of oral MK-8189 dose-matched placebo treatment (Period 1), followed by a single intramuscular (IM) injection of MK-5720 dose-matched placebo treatment (Period 2).
Period 1 STARTED	6	7	4
Period 1 Treated	6	7	4
Period 1 COMPLETED	6	6	4
Period 1 NOT COMPLETED	0	1	0
Period 2 STARTED	6	6	4
Period 2 COMPLETED	6	5	3
Period 2 NOT COMPLETED	0	1	1

Reasons for withdrawal

Reasons for withdrawal
Measure	Panel A: Period 1 MK-8189 4 mg → Period 2 MK-5720 35mg Participants received 7 days of oral MK-8189 4 mg (Period 1), followed by a single intramuscular (IM) injection of MK-5720 35 mg (Period 2).	Panel B: Period 1 MK-8189 8 mg → Period 2 MK-5720 70 mg Participants received 7 days of oral MK-8189 8 mg (Period 1), followed by a single IM injection of MK-5720 70 mg (Period 2).	Placebo Period 1 → Placebo Period 2 Participants received 7 days of oral MK-8189 dose-matched placebo treatment (Period 1), followed by a single intramuscular (IM) injection of MK-5720 dose-matched placebo treatment (Period 2).	Panel C: Period 1 MK-8189 16 mg → Period 2 MK-5720 140 mg Participants received 7 days of oral MK-8189 16 mg (Period 1), followed by a single IM injection of MK-5720 140 mg (Period 2). No participants were enrolled into this arm.	Panel D: Period 1 MK-8189 24 mg → Period 2 MK-5720 280 mg Participants received 7 days of oral MK-8189 24 mg (Period 1), followed by a single IM injection of MK-5720 280 mg (Period 2). No participants were enrolled into this arm.	Panel E: Period 1 MK-8189 48 mg → Period 2 MK-5720 560 mg Participants received 7 days of oral MK-8189 48 mg (Period 1), followed by a single IM injection of MK-5720 560 mg (Period 2). No participants were enrolled into this arm.	Panel F: Period 1 MK-8189 48 mg → Period 2 MK-5720 560 mg Participants received 7 days of oral MK-8189 48 mg (Period 1), followed by a single IM injection of MK-5720 560 mg (Period 2), after a Pharmacokinetic (PK) break following Panel E. No participants were enrolled into this arm.	Panels C, D, E, and F: Placebo Period 1 → Placebo Period 2 Participants received 7 days of oral MK-8189 dose-matched placebo treatment (Period 1), followed by a single intramuscular (IM) injection of MK-5720 dose-matched placebo (Period 2). No participants were enrolled into this arm.
Period 1 Physician Decision	0	1	0	0	0	0	0	0
Period 2 Withdrawal by Subject	0	1	1	0	0	0	0	0

Baseline Characteristics

A Study of MK-5720 in Participants With Schizophrenia (MK-5720-001)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Panel A: Period 1 MK-8189 4 mg → Period 2 MK-5720 35mg n=6 Participants Participants received 7 days of oral MK-8189 4 mg (Period 1), followed by a single intramuscular (IM) injection of MK-5720 35 mg (Period 2).	Panel B: Period 1 MK-8189 8 mg → Period 2 MK-5720 70 mg n=7 Participants Participants received 7 days of oral MK-8189 8 mg (Period 1), followed by a single IM injection of MK-5720 70 mg (Period 2).	Placebo Period 1 → Placebo Period 2 n=4 Participants Participants received 7 days of oral MK-8189 dose-matched placebo treatment (Period 1), followed by a single intramuscular (IM) injection of MK-5720 dose-matched placebo treatment (Period 2).	Total n=17 Participants Total of all reporting groups
Age, Continuous	45.8 Years STANDARD_DEVIATION 9.4 • n=5 Participants	46.3 Years STANDARD_DEVIATION 11.3 • n=7 Participants	51.5 Years STANDARD_DEVIATION 5.8 • n=5 Participants	47.4 Years STANDARD_DEVIATION 9.3 • n=4 Participants
Sex: Female, Male Female	0 Participants n=5 Participants	2 Participants n=7 Participants	1 Participants n=5 Participants	3 Participants n=4 Participants
Sex: Female, Male Male	6 Participants n=5 Participants	5 Participants n=7 Participants	3 Participants n=5 Participants	14 Participants n=4 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	0 Participants n=5 Participants	4 Participants n=7 Participants	0 Participants n=5 Participants	4 Participants n=4 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	6 Participants n=5 Participants	3 Participants n=7 Participants	4 Participants n=5 Participants	13 Participants n=4 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants
Race (NIH/OMB) Asian	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants
Race (NIH/OMB) Black or African American	6 Participants n=5 Participants	3 Participants n=7 Participants	3 Participants n=5 Participants	12 Participants n=4 Participants
Race (NIH/OMB) White	0 Participants n=5 Participants	4 Participants n=7 Participants	1 Participants n=5 Participants	5 Participants n=4 Participants
Race (NIH/OMB) More than one race	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants

PRIMARY outcome

Timeframe: Up to approximately 10 days

Population: All participants in Period 1 who received at least one dose of study treatment and had data available for Period 1. Panels C, D, E, and F were not enrolled, and no data was collected for this outcome measure.

An adverse event (AE) is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experienced one or more AEs is reported here for participants in Period 1. Per protocol, this outcome measure has been reported by panel and dose. As specified by the protocol, Period 2 has been analyzed separately and reported later in the record.

Outcome measures

Outcome measures
Measure	Panel A: Period 1 MK-8189 4 mg n=6 Participants Participants received 7 days of oral MK-8189 4 mg (Period 1), followed by a single intramuscular (IM) injection of MK-5720 35 mg (Period 2).	Panel B: Period 1 MK-8189 8 mg n=7 Participants Participants received 7 days of oral MK-8189 8 mg (Period 1), followed by a single IM injection of MK-5720 70 mg (Period 2).	Placebo Period 1 n=4 Participants Participants received 7 days of oral MK-8189 dose-matched placebo treatment (Period 1), followed by a single intramuscular (IM) injection of MK-5720 dose-matched placebo treatment (Period 2).	Panel C: Period 1 MK-8189 16 mg Participants received 7 days of oral MK-8189 16 mg (Period 1), followed by a single IM injection of MK-5720 140 mg (Period 2). No participants were enrolled into this arm.	Panel D: Period 1 MK-8189 24 mg Participants received 7 days of oral MK-8189 24 mg (Period 1), followed by a single IM injection of MK-5720 280 mg (Period 2). No participants were enrolled into this arm.	Panel E: Period 1 MK-8189 48 mg Participants received 7 days of oral MK-8189 48 mg (Period 1), followed by a single IM injection of MK-5720 560 mg (Period 2). No participants were enrolled into this arm.	Panel F: Period 1 MK-8189 48 mg Participants received 7 days of oral MK-8189 48 mg (Period 1), followed by a single IM injection of MK-5720 560 mg (Period 2), after a Pharmacokinetic (PK) break following Panel E. No participants were enrolled into this arm.	Panels C, D, E, and F: Placebo Period 1 Participants received 7 days of oral MK-8189 dose-matched placebo treatment (Period 1), followed by a single intramuscular (IM) injection of MK-5720 dose-matched placebo (Period 2). No participants were enrolled into this arm.
Number of Participants Who Experience ≥1 Adverse Event (AE) in Period 1	1 Participants	4 Participants	2 Participants	—	—	—	—	—

PRIMARY outcome

Timeframe: Up to approximately 72 days

Population: All participants in Period 2 who received at least one dose of study treatment and had data available for Period 2. In Panel B 1 participant discontinued treatment between Period 1 and Period 2. Panels C, D, E, and F were not enrolled, and no data was collected for this outcome measure.

An adverse event (AE) is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experienced one or more AEs is reported here for participants in Period 2. Per protocol, this outcome measure has been reported by panel and dose. As specified by the protocol, Period 1 has been analyzed separately and reported earlier in the record.

Outcome measures

Outcome measures
Measure	Panel A: Period 1 MK-8189 4 mg n=6 Participants Participants received 7 days of oral MK-8189 4 mg (Period 1), followed by a single intramuscular (IM) injection of MK-5720 35 mg (Period 2).	Panel B: Period 1 MK-8189 8 mg n=6 Participants Participants received 7 days of oral MK-8189 8 mg (Period 1), followed by a single IM injection of MK-5720 70 mg (Period 2).	Placebo Period 1 n=4 Participants Participants received 7 days of oral MK-8189 dose-matched placebo treatment (Period 1), followed by a single intramuscular (IM) injection of MK-5720 dose-matched placebo treatment (Period 2).	Panel C: Period 1 MK-8189 16 mg Participants received 7 days of oral MK-8189 16 mg (Period 1), followed by a single IM injection of MK-5720 140 mg (Period 2). No participants were enrolled into this arm.	Panel D: Period 1 MK-8189 24 mg Participants received 7 days of oral MK-8189 24 mg (Period 1), followed by a single IM injection of MK-5720 280 mg (Period 2). No participants were enrolled into this arm.	Panel E: Period 1 MK-8189 48 mg Participants received 7 days of oral MK-8189 48 mg (Period 1), followed by a single IM injection of MK-5720 560 mg (Period 2). No participants were enrolled into this arm.	Panel F: Period 1 MK-8189 48 mg Participants received 7 days of oral MK-8189 48 mg (Period 1), followed by a single IM injection of MK-5720 560 mg (Period 2), after a Pharmacokinetic (PK) break following Panel E. No participants were enrolled into this arm.	Panels C, D, E, and F: Placebo Period 1 Participants received 7 days of oral MK-8189 dose-matched placebo treatment (Period 1), followed by a single intramuscular (IM) injection of MK-5720 dose-matched placebo (Period 2). No participants were enrolled into this arm.
Number of Participants Who Experience ≥1 AE(s) in Period 2	1 Participants	2 Participants	1 Participants	—	—	—	—	—

PRIMARY outcome

Timeframe: Up to approximately 10 days

Population: All participants in Period 1 who received at least one dose of study treatment and had data available for Period 1. Panels C, D, E, and F were not enrolled, and no data was collected for this outcome measure.

An adverse event (AE) is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinued study treatment due to an AE is reported here for participants in Period 1. Per protocol, this outcome measure has been reported by panel and dose. As specified by the protocol, Period 2 has been analyzed separately and reported later in the record.

Outcome measures

Outcome measures
Measure	Panel A: Period 1 MK-8189 4 mg n=6 Participants Participants received 7 days of oral MK-8189 4 mg (Period 1), followed by a single intramuscular (IM) injection of MK-5720 35 mg (Period 2).	Panel B: Period 1 MK-8189 8 mg n=7 Participants Participants received 7 days of oral MK-8189 8 mg (Period 1), followed by a single IM injection of MK-5720 70 mg (Period 2).	Placebo Period 1 n=4 Participants Participants received 7 days of oral MK-8189 dose-matched placebo treatment (Period 1), followed by a single intramuscular (IM) injection of MK-5720 dose-matched placebo treatment (Period 2).	Panel C: Period 1 MK-8189 16 mg Participants received 7 days of oral MK-8189 16 mg (Period 1), followed by a single IM injection of MK-5720 140 mg (Period 2). No participants were enrolled into this arm.	Panel D: Period 1 MK-8189 24 mg Participants received 7 days of oral MK-8189 24 mg (Period 1), followed by a single IM injection of MK-5720 280 mg (Period 2). No participants were enrolled into this arm.	Panel E: Period 1 MK-8189 48 mg Participants received 7 days of oral MK-8189 48 mg (Period 1), followed by a single IM injection of MK-5720 560 mg (Period 2). No participants were enrolled into this arm.	Panel F: Period 1 MK-8189 48 mg Participants received 7 days of oral MK-8189 48 mg (Period 1), followed by a single IM injection of MK-5720 560 mg (Period 2), after a Pharmacokinetic (PK) break following Panel E. No participants were enrolled into this arm.	Panels C, D, E, and F: Placebo Period 1 Participants received 7 days of oral MK-8189 dose-matched placebo treatment (Period 1), followed by a single intramuscular (IM) injection of MK-5720 dose-matched placebo (Period 2). No participants were enrolled into this arm.
Number of Participants Who Discontinue Study Due to an AE in Period 1	0 Participants	1 Participants	0 Participants	—	—	—	—	—

PRIMARY outcome

Timeframe: Up to approximately 72 days

Population: All participants in Period 2 who received at least one dose of study treatment and had data available for Period 2. In Panel B 1 participant discontinued treatment between Period 1 and Period 2. Panels C, D, E, and F were not enrolled, and no data was collected for this outcome measure.

An adverse event (AE) is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinued study treatment due to an AE is reported here for participants in Period 2. Per protocol, this outcome measure has been reported by panel and dose. As specified by the protocol, Period 1 has been analyzed separately and reported earlier in the record.

Outcome measures

Outcome measures
Measure	Panel A: Period 1 MK-8189 4 mg n=6 Participants Participants received 7 days of oral MK-8189 4 mg (Period 1), followed by a single intramuscular (IM) injection of MK-5720 35 mg (Period 2).	Panel B: Period 1 MK-8189 8 mg n=6 Participants Participants received 7 days of oral MK-8189 8 mg (Period 1), followed by a single IM injection of MK-5720 70 mg (Period 2).	Placebo Period 1 n=4 Participants Participants received 7 days of oral MK-8189 dose-matched placebo treatment (Period 1), followed by a single intramuscular (IM) injection of MK-5720 dose-matched placebo treatment (Period 2).	Panel C: Period 1 MK-8189 16 mg Participants received 7 days of oral MK-8189 16 mg (Period 1), followed by a single IM injection of MK-5720 140 mg (Period 2). No participants were enrolled into this arm.	Panel D: Period 1 MK-8189 24 mg Participants received 7 days of oral MK-8189 24 mg (Period 1), followed by a single IM injection of MK-5720 280 mg (Period 2). No participants were enrolled into this arm.	Panel E: Period 1 MK-8189 48 mg Participants received 7 days of oral MK-8189 48 mg (Period 1), followed by a single IM injection of MK-5720 560 mg (Period 2). No participants were enrolled into this arm.	Panel F: Period 1 MK-8189 48 mg Participants received 7 days of oral MK-8189 48 mg (Period 1), followed by a single IM injection of MK-5720 560 mg (Period 2), after a Pharmacokinetic (PK) break following Panel E. No participants were enrolled into this arm.	Panels C, D, E, and F: Placebo Period 1 Participants received 7 days of oral MK-8189 dose-matched placebo treatment (Period 1), followed by a single intramuscular (IM) injection of MK-5720 dose-matched placebo (Period 2). No participants were enrolled into this arm.
Number of Participants Who Discontinue Study Due to an AE in Period 2	0 Participants	0 Participants	0 Participants	—	—	—	—	—

PRIMARY outcome

Timeframe: Predose, 0.5, 1, 2, 4, 6, 24, 48, 96, 120, 144, 168, 192, 216, 264, 288, 312, 336, 360, 384, 432, 456, 504, 672, 840, 1008, 1176, and 1320 hours postdose

Population: Per protocol population includes all participants who complied with the protocol, had received MK-8189 treatment in Period 1 and MK-5720 treatment in Period 2, and had data available. Per protocol, placebo arms were not included in any PK outcome analyses. Panels C, D, E, and F were not enrolled, and no data was collected for this outcome measure.

AUC0-last was defined as the area under the concentration-time curve from time zero to time of last measurable concentration of MK-5720. Blood samples were collected at specified intervals were used to estimate AUC0-last following a single dose administration of MK-5720 in Period 2. Per protocol, this outcome measure has been reported by panel and dose.

Outcome measures

Outcome measures
Measure	Panel A: Period 1 MK-8189 4 mg n=6 Participants Participants received 7 days of oral MK-8189 4 mg (Period 1), followed by a single intramuscular (IM) injection of MK-5720 35 mg (Period 2).	Panel B: Period 1 MK-8189 8 mg n=6 Participants Participants received 7 days of oral MK-8189 8 mg (Period 1), followed by a single IM injection of MK-5720 70 mg (Period 2).	Placebo Period 1 Participants received 7 days of oral MK-8189 dose-matched placebo treatment (Period 1), followed by a single intramuscular (IM) injection of MK-5720 dose-matched placebo treatment (Period 2).	Panel C: Period 1 MK-8189 16 mg Participants received 7 days of oral MK-8189 16 mg (Period 1), followed by a single IM injection of MK-5720 140 mg (Period 2). No participants were enrolled into this arm.	Panel D: Period 1 MK-8189 24 mg Participants received 7 days of oral MK-8189 24 mg (Period 1), followed by a single IM injection of MK-5720 280 mg (Period 2). No participants were enrolled into this arm.	Panel E: Period 1 MK-8189 48 mg Participants received 7 days of oral MK-8189 48 mg (Period 1), followed by a single IM injection of MK-5720 560 mg (Period 2). No participants were enrolled into this arm.	Panel F: Period 1 MK-8189 48 mg Participants received 7 days of oral MK-8189 48 mg (Period 1), followed by a single IM injection of MK-5720 560 mg (Period 2), after a Pharmacokinetic (PK) break following Panel E. No participants were enrolled into this arm.	Panels C, D, E, and F: Placebo Period 1 Participants received 7 days of oral MK-8189 dose-matched placebo treatment (Period 1), followed by a single intramuscular (IM) injection of MK-5720 dose-matched placebo (Period 2). No participants were enrolled into this arm.
Area Under the Concentration-Time Curve From Time 0 to Last Quantifiable Concentration (AUC0-last) of MK-5720	34.3 hr*nM Geometric Coefficient of Variation 128.3	73.3 hr*nM Geometric Coefficient of Variation 96.2	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Predose, 0.5, 1, 2, 4, 6, 24, 48, 96, 120, 144, 168, 192, 216, 264, 288, 312, 336, 360, 384, 432, 456, 504, 672, 840, 1008, 1176, and 1320 hours postdose

Population: Per protocol population includes all participants who complied with the protocol, had received MK-8189 treatment in Period 1 and MK-5720 treatment in Period 2, and had data available. Per protocol, placebo arms were not included in any PK outcome analyses. Panels C, D, E, and F were not enrolled, and no data was collected for this outcome measure.

AUC0-inf is defined as the area under concentration-time curve of MK-5720 from time zero to infinity. Blood samples were collected at specified intervals for the determination of AUC-inf following a single dose administration of MK-5720 in Period 2. Per protocol, this outcome measure has been reported by panel and dose.

Outcome measures

Outcome measures
Measure	Panel A: Period 1 MK-8189 4 mg n=2 Participants Participants received 7 days of oral MK-8189 4 mg (Period 1), followed by a single intramuscular (IM) injection of MK-5720 35 mg (Period 2).	Panel B: Period 1 MK-8189 8 mg n=6 Participants Participants received 7 days of oral MK-8189 8 mg (Period 1), followed by a single IM injection of MK-5720 70 mg (Period 2).	Placebo Period 1 Participants received 7 days of oral MK-8189 dose-matched placebo treatment (Period 1), followed by a single intramuscular (IM) injection of MK-5720 dose-matched placebo treatment (Period 2).	Panel C: Period 1 MK-8189 16 mg Participants received 7 days of oral MK-8189 16 mg (Period 1), followed by a single IM injection of MK-5720 140 mg (Period 2). No participants were enrolled into this arm.	Panel D: Period 1 MK-8189 24 mg Participants received 7 days of oral MK-8189 24 mg (Period 1), followed by a single IM injection of MK-5720 280 mg (Period 2). No participants were enrolled into this arm.	Panel E: Period 1 MK-8189 48 mg Participants received 7 days of oral MK-8189 48 mg (Period 1), followed by a single IM injection of MK-5720 560 mg (Period 2). No participants were enrolled into this arm.	Panel F: Period 1 MK-8189 48 mg Participants received 7 days of oral MK-8189 48 mg (Period 1), followed by a single IM injection of MK-5720 560 mg (Period 2), after a Pharmacokinetic (PK) break following Panel E. No participants were enrolled into this arm.	Panels C, D, E, and F: Placebo Period 1 Participants received 7 days of oral MK-8189 dose-matched placebo treatment (Period 1), followed by a single intramuscular (IM) injection of MK-5720 dose-matched placebo (Period 2). No participants were enrolled into this arm.
Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC-inf) of MK-5720	70.0 hr*nM Geometric Coefficient of Variation 61.6	134 hr*nM Geometric Coefficient of Variation 61.6	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Predose, 0.5, 1, 2, 4, 6, 24, 48, 96, 120, 144, 168, 192, 216, 264, 288, 312, 336, 360, 384, 432, 456, 504, 672, 840, 1008, 1176, and 1320 hours postdose

Population: Per protocol population includes all participants who complied with the protocol, had received MK-8189 treatment in Period 1 and MK-5720 treatment in Period 2, and had data available. Per protocol, placebo arms were not included in any PK outcome analyses. Panels C, D, E, and F were not enrolled, and no data was collected for this outcome measure.

Cmax is defined as the maximum concentration of MK-5720 reached. Blood samples were collected at specified intervals for the determination of Cmax following a single dose administration of MK-5720 in Period 2. Per protocol, this outcome measure has been reported by panel and dose.

Outcome measures

Outcome measures
Measure	Panel A: Period 1 MK-8189 4 mg n=6 Participants Participants received 7 days of oral MK-8189 4 mg (Period 1), followed by a single intramuscular (IM) injection of MK-5720 35 mg (Period 2).	Panel B: Period 1 MK-8189 8 mg n=6 Participants Participants received 7 days of oral MK-8189 8 mg (Period 1), followed by a single IM injection of MK-5720 70 mg (Period 2).	Placebo Period 1 Participants received 7 days of oral MK-8189 dose-matched placebo treatment (Period 1), followed by a single intramuscular (IM) injection of MK-5720 dose-matched placebo treatment (Period 2).	Panel C: Period 1 MK-8189 16 mg Participants received 7 days of oral MK-8189 16 mg (Period 1), followed by a single IM injection of MK-5720 140 mg (Period 2). No participants were enrolled into this arm.	Panel D: Period 1 MK-8189 24 mg Participants received 7 days of oral MK-8189 24 mg (Period 1), followed by a single IM injection of MK-5720 280 mg (Period 2). No participants were enrolled into this arm.	Panel E: Period 1 MK-8189 48 mg Participants received 7 days of oral MK-8189 48 mg (Period 1), followed by a single IM injection of MK-5720 560 mg (Period 2). No participants were enrolled into this arm.	Panel F: Period 1 MK-8189 48 mg Participants received 7 days of oral MK-8189 48 mg (Period 1), followed by a single IM injection of MK-5720 560 mg (Period 2), after a Pharmacokinetic (PK) break following Panel E. No participants were enrolled into this arm.	Panels C, D, E, and F: Placebo Period 1 Participants received 7 days of oral MK-8189 dose-matched placebo treatment (Period 1), followed by a single intramuscular (IM) injection of MK-5720 dose-matched placebo (Period 2). No participants were enrolled into this arm.
Maximum Serum Concentration (Cmax) of MK-5720	0.165 nM Geometric Coefficient of Variation 156.2	0.473 nM Geometric Coefficient of Variation 105.1	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Predose, 0.5, 1, 2, 4, 6, 24, 48, 96, 120, 144, 168, 192, 216, 264, 288, 312, 336, 360, 384, 432, 456, 504, 672, 840, 1008, 1176, and 1320 hours postdose

Population: Per protocol population includes all participants who complied with the protocol, had received MK-8189 treatment in Period 1 and MK-5720 treatment in Period 2, and had data available. Per protocol, placebo arms were not included in any PK outcome analyses. Panels C, D, E, and F were not enrolled, and no data was collected for this outcome measure.

Tmax is defined as the time to maximum concentration of MK-5720 reached. Blood samples were collected at specified intervals for the determination of Tmax following a single dose administration of MK-5720 in Period 2. Per protocol, this outcome measure has been reported by panel and dose.

Outcome measures

Outcome measures
Measure	Panel A: Period 1 MK-8189 4 mg n=6 Participants Participants received 7 days of oral MK-8189 4 mg (Period 1), followed by a single intramuscular (IM) injection of MK-5720 35 mg (Period 2).	Panel B: Period 1 MK-8189 8 mg n=6 Participants Participants received 7 days of oral MK-8189 8 mg (Period 1), followed by a single IM injection of MK-5720 70 mg (Period 2).	Placebo Period 1 Participants received 7 days of oral MK-8189 dose-matched placebo treatment (Period 1), followed by a single intramuscular (IM) injection of MK-5720 dose-matched placebo treatment (Period 2).	Panel C: Period 1 MK-8189 16 mg Participants received 7 days of oral MK-8189 16 mg (Period 1), followed by a single IM injection of MK-5720 140 mg (Period 2). No participants were enrolled into this arm.	Panel D: Period 1 MK-8189 24 mg Participants received 7 days of oral MK-8189 24 mg (Period 1), followed by a single IM injection of MK-5720 280 mg (Period 2). No participants were enrolled into this arm.	Panel E: Period 1 MK-8189 48 mg Participants received 7 days of oral MK-8189 48 mg (Period 1), followed by a single IM injection of MK-5720 560 mg (Period 2). No participants were enrolled into this arm.	Panel F: Period 1 MK-8189 48 mg Participants received 7 days of oral MK-8189 48 mg (Period 1), followed by a single IM injection of MK-5720 560 mg (Period 2), after a Pharmacokinetic (PK) break following Panel E. No participants were enrolled into this arm.	Panels C, D, E, and F: Placebo Period 1 Participants received 7 days of oral MK-8189 dose-matched placebo treatment (Period 1), followed by a single intramuscular (IM) injection of MK-5720 dose-matched placebo (Period 2). No participants were enrolled into this arm.
Time to Maximum Concentration (Tmax) of MK-5720	48.00 hr Interval 0.5 to 96.0	108.00 hr Interval 4.0 to 192.12	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Predose, 0.5, 1, 2, 4, 6, 24, 48, 96, 120, 144, 168, 192, 216, 264, 288, 312, 336, 360, 384, 432, 456, 504, 672, 840, 1008, 1176, and 1320 hours postdose

Population: Per protocol population includes all participants who complied with the protocol, had received MK-8189 treatment in Period 1 and MK-5720 treatment in Period 2, and had data available. Per protocol, placebo arms were not included in any PK outcome analyses. Panels C, D, E, and F were not enrolled, and no data was collected for this outcome measure.

CL/F is the rate at which the MK-5720 is completely removed from plasma. Blood samples were collected at specified intervals for the determination of CL/F following a single dose administration of MK-5720 in Period 2. Per protocol, this outcome measure has been reported by panel and dose.

Outcome measures

Outcome measures
Measure	Panel A: Period 1 MK-8189 4 mg n=2 Participants Participants received 7 days of oral MK-8189 4 mg (Period 1), followed by a single intramuscular (IM) injection of MK-5720 35 mg (Period 2).	Panel B: Period 1 MK-8189 8 mg n=6 Participants Participants received 7 days of oral MK-8189 8 mg (Period 1), followed by a single IM injection of MK-5720 70 mg (Period 2).	Placebo Period 1 Participants received 7 days of oral MK-8189 dose-matched placebo treatment (Period 1), followed by a single intramuscular (IM) injection of MK-5720 dose-matched placebo treatment (Period 2).	Panel C: Period 1 MK-8189 16 mg Participants received 7 days of oral MK-8189 16 mg (Period 1), followed by a single IM injection of MK-5720 140 mg (Period 2). No participants were enrolled into this arm.	Panel D: Period 1 MK-8189 24 mg Participants received 7 days of oral MK-8189 24 mg (Period 1), followed by a single IM injection of MK-5720 280 mg (Period 2). No participants were enrolled into this arm.	Panel E: Period 1 MK-8189 48 mg Participants received 7 days of oral MK-8189 48 mg (Period 1), followed by a single IM injection of MK-5720 560 mg (Period 2). No participants were enrolled into this arm.	Panel F: Period 1 MK-8189 48 mg Participants received 7 days of oral MK-8189 48 mg (Period 1), followed by a single IM injection of MK-5720 560 mg (Period 2), after a Pharmacokinetic (PK) break following Panel E. No participants were enrolled into this arm.	Panels C, D, E, and F: Placebo Period 1 Participants received 7 days of oral MK-8189 dose-matched placebo treatment (Period 1), followed by a single intramuscular (IM) injection of MK-5720 dose-matched placebo (Period 2). No participants were enrolled into this arm.
Apparent Clearance (CL/F) of MK-5720	892 Liters/hr Geometric Coefficient of Variation 61.6	933 Liters/hr Geometric Coefficient of Variation 61.6	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Predose, 0.5, 1, 2, 4, 6, 24, 48, 96, 120, 144, 168, 192, 216, 264, 288, 312, 336, 360, 384, 432, 456, 504, 672, 840, 1008, 1176, and 1320 hours postdose

Population: Per protocol population includes all participants who complied with the protocol, had received MK-8189 treatment in Period 1 and MK-5720 treatment in Period 2, and had data available. Per protocol, placebo arms were not included in any PK outcome analyses. Panels C, D, E, and F were not enrolled, and no data was collected for this outcome measure.

Vz/F is the apparent volume of distribution of MK-5720. Blood samples were collected at specified intervals for the determination of Vz/F following a single dose administration of MK-5720 in Period 2. Per protocol, this outcome measure has been reported by panel and dose.

Outcome measures

Outcome measures
Measure	Panel A: Period 1 MK-8189 4 mg n=2 Participants Participants received 7 days of oral MK-8189 4 mg (Period 1), followed by a single intramuscular (IM) injection of MK-5720 35 mg (Period 2).	Panel B: Period 1 MK-8189 8 mg n=6 Participants Participants received 7 days of oral MK-8189 8 mg (Period 1), followed by a single IM injection of MK-5720 70 mg (Period 2).	Placebo Period 1 Participants received 7 days of oral MK-8189 dose-matched placebo treatment (Period 1), followed by a single intramuscular (IM) injection of MK-5720 dose-matched placebo treatment (Period 2).	Panel C: Period 1 MK-8189 16 mg Participants received 7 days of oral MK-8189 16 mg (Period 1), followed by a single IM injection of MK-5720 140 mg (Period 2). No participants were enrolled into this arm.	Panel D: Period 1 MK-8189 24 mg Participants received 7 days of oral MK-8189 24 mg (Period 1), followed by a single IM injection of MK-5720 280 mg (Period 2). No participants were enrolled into this arm.	Panel E: Period 1 MK-8189 48 mg Participants received 7 days of oral MK-8189 48 mg (Period 1), followed by a single IM injection of MK-5720 560 mg (Period 2). No participants were enrolled into this arm.	Panel F: Period 1 MK-8189 48 mg Participants received 7 days of oral MK-8189 48 mg (Period 1), followed by a single IM injection of MK-5720 560 mg (Period 2), after a Pharmacokinetic (PK) break following Panel E. No participants were enrolled into this arm.	Panels C, D, E, and F: Placebo Period 1 Participants received 7 days of oral MK-8189 dose-matched placebo treatment (Period 1), followed by a single intramuscular (IM) injection of MK-5720 dose-matched placebo (Period 2). No participants were enrolled into this arm.
Apparent Volume of Distribution (Vz/F) of MK-5720	55400 Liters Geometric Coefficient of Variation 83.2	218000 Liters Geometric Coefficient of Variation 243.8	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Predose, 0.5, 1, 2, 4, 6, 24, 48, 96, 120, 144, 168, 192, 216, 264, 288, 312, 336, 360, 384, 432, 456, 504, 672, 840, 1008, 1176, and 1320 hours postdose

Population: Per protocol population includes all participants who complied with the protocol, had received MK-8189 treatment in Period 1 and MK-5720 treatment in Period 2, and had data available. Per protocol, placebo arms were not included in any PK outcome analyses. Panels C, D, E, and F were not enrolled, and no data was collected for this outcome measure.

t1/2 is defined as the time required to divide plasma concentration of MK-5720 by half after reaching pseudo-equilibrium. Blood samples were collected at specified intervals for the determination t1/2 following a single dose administration of MK-5720 in Period 2. Per protocol, this outcome measure has been reported by panel and dose.

Outcome measures

Outcome measures
Measure	Panel A: Period 1 MK-8189 4 mg n=2 Participants Participants received 7 days of oral MK-8189 4 mg (Period 1), followed by a single intramuscular (IM) injection of MK-5720 35 mg (Period 2).	Panel B: Period 1 MK-8189 8 mg n=6 Participants Participants received 7 days of oral MK-8189 8 mg (Period 1), followed by a single IM injection of MK-5720 70 mg (Period 2).	Placebo Period 1 Participants received 7 days of oral MK-8189 dose-matched placebo treatment (Period 1), followed by a single intramuscular (IM) injection of MK-5720 dose-matched placebo treatment (Period 2).	Panel C: Period 1 MK-8189 16 mg Participants received 7 days of oral MK-8189 16 mg (Period 1), followed by a single IM injection of MK-5720 140 mg (Period 2). No participants were enrolled into this arm.	Panel D: Period 1 MK-8189 24 mg Participants received 7 days of oral MK-8189 24 mg (Period 1), followed by a single IM injection of MK-5720 280 mg (Period 2). No participants were enrolled into this arm.	Panel E: Period 1 MK-8189 48 mg Participants received 7 days of oral MK-8189 48 mg (Period 1), followed by a single IM injection of MK-5720 560 mg (Period 2). No participants were enrolled into this arm.	Panel F: Period 1 MK-8189 48 mg Participants received 7 days of oral MK-8189 48 mg (Period 1), followed by a single IM injection of MK-5720 560 mg (Period 2), after a Pharmacokinetic (PK) break following Panel E. No participants were enrolled into this arm.	Panels C, D, E, and F: Placebo Period 1 Participants received 7 days of oral MK-8189 dose-matched placebo treatment (Period 1), followed by a single intramuscular (IM) injection of MK-5720 dose-matched placebo (Period 2). No participants were enrolled into this arm.
Apparent Terminal Half-life (t1/2) of MK-5720	43.0 hr Geometric Coefficient of Variation 15.9	162 hr Geometric Coefficient of Variation 271.2	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Predose, 0.5, 1, 2, 4, 6, 24, 48, 96, 120, 144, 168, 192, 216, 264, 288, 312, 336, 360, 384, 432, 456, 504, and 672 hours postdose

Population: Per protocol population includes all participants who complied with the protocol, had received MK-8189 treatment in Period 1 and MK-5720 treatment in Period 2, and had data available. Per protocol, placebo arms were not included in any PK outcome analyses. Panels C, D, E, and F were not enrolled, and no data was collected for this outcome measure.

AUC0-28d is defined as the area under the concentration-time curve from time zero to 28 days of MK-8189 (a metabolite of MK-5720). Blood samples were collected at specified intervals for the determination of AUC0-28d for MK-8189 following a single dose administration of MK-5720 in Period 2. Per protocol, this outcome measure has been reported by panel and dose.

Outcome measures

Outcome measures
Measure	Panel A: Period 1 MK-8189 4 mg n=6 Participants Participants received 7 days of oral MK-8189 4 mg (Period 1), followed by a single intramuscular (IM) injection of MK-5720 35 mg (Period 2).	Panel B: Period 1 MK-8189 8 mg n=6 Participants Participants received 7 days of oral MK-8189 8 mg (Period 1), followed by a single IM injection of MK-5720 70 mg (Period 2).	Placebo Period 1 Participants received 7 days of oral MK-8189 dose-matched placebo treatment (Period 1), followed by a single intramuscular (IM) injection of MK-5720 dose-matched placebo treatment (Period 2).	Panel C: Period 1 MK-8189 16 mg Participants received 7 days of oral MK-8189 16 mg (Period 1), followed by a single IM injection of MK-5720 140 mg (Period 2). No participants were enrolled into this arm.	Panel D: Period 1 MK-8189 24 mg Participants received 7 days of oral MK-8189 24 mg (Period 1), followed by a single IM injection of MK-5720 280 mg (Period 2). No participants were enrolled into this arm.	Panel E: Period 1 MK-8189 48 mg Participants received 7 days of oral MK-8189 48 mg (Period 1), followed by a single IM injection of MK-5720 560 mg (Period 2). No participants were enrolled into this arm.	Panel F: Period 1 MK-8189 48 mg Participants received 7 days of oral MK-8189 48 mg (Period 1), followed by a single IM injection of MK-5720 560 mg (Period 2), after a Pharmacokinetic (PK) break following Panel E. No participants were enrolled into this arm.	Panels C, D, E, and F: Placebo Period 1 Participants received 7 days of oral MK-8189 dose-matched placebo treatment (Period 1), followed by a single intramuscular (IM) injection of MK-5720 dose-matched placebo (Period 2). No participants were enrolled into this arm.
Area Under the Concentration-Time Curve From Time 0 to 28 Days (AUC0-28d) of MK-8189	2850 hr*nM Geometric Coefficient of Variation 4121.1	29800 hr*nM Geometric Coefficient of Variation 89.3	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Predose, 0.5, 1, 2, 4, 6, 24, 48, 96, 120, 144, 168, 192, 216, 264, 288, 312, 336, 360, 384, 432, 456, 504, 672, 840, 1008, 1176, and 1320 hours postdose

Population: Per protocol population includes all participants who complied with the protocol, had received MK-8189 treatment in Period 1 and MK-5720 treatment in Period 2, and had data available. Per protocol, placebo arms were not included in any PK outcome analyses. Panels C, D, E, and F were not enrolled, and no data was collected for this outcome measure.

AUC0-inf is defined as the area under concentration-time curve from time zero to infinity of MK-8189 (a metabolite of MK-5720). Blood samples were collected at specified intervals for the determination of AUC0-inf for MK-8198 following a single dose administration of MK-5720 in Period 2. Per protocol, this outcome measure has been reported by panel and dose.

Outcome measures

Outcome measures
Measure	Panel A: Period 1 MK-8189 4 mg n=4 Participants Participants received 7 days of oral MK-8189 4 mg (Period 1), followed by a single intramuscular (IM) injection of MK-5720 35 mg (Period 2).	Panel B: Period 1 MK-8189 8 mg n=6 Participants Participants received 7 days of oral MK-8189 8 mg (Period 1), followed by a single IM injection of MK-5720 70 mg (Period 2).	Placebo Period 1 Participants received 7 days of oral MK-8189 dose-matched placebo treatment (Period 1), followed by a single intramuscular (IM) injection of MK-5720 dose-matched placebo treatment (Period 2).	Panel C: Period 1 MK-8189 16 mg Participants received 7 days of oral MK-8189 16 mg (Period 1), followed by a single IM injection of MK-5720 140 mg (Period 2). No participants were enrolled into this arm.	Panel D: Period 1 MK-8189 24 mg Participants received 7 days of oral MK-8189 24 mg (Period 1), followed by a single IM injection of MK-5720 280 mg (Period 2). No participants were enrolled into this arm.	Panel E: Period 1 MK-8189 48 mg Participants received 7 days of oral MK-8189 48 mg (Period 1), followed by a single IM injection of MK-5720 560 mg (Period 2). No participants were enrolled into this arm.	Panel F: Period 1 MK-8189 48 mg Participants received 7 days of oral MK-8189 48 mg (Period 1), followed by a single IM injection of MK-5720 560 mg (Period 2), after a Pharmacokinetic (PK) break following Panel E. No participants were enrolled into this arm.	Panels C, D, E, and F: Placebo Period 1 Participants received 7 days of oral MK-8189 dose-matched placebo treatment (Period 1), followed by a single intramuscular (IM) injection of MK-5720 dose-matched placebo (Period 2). No participants were enrolled into this arm.
AUC0-inf of MK-8189	8400 hr*nM Geometric Coefficient of Variation 75.3	31900 hr*nM Geometric Coefficient of Variation 93.9	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Predose, 0.5, 1, 2, 4, 6, 24, 48, 96, 120, 144, 168, 192, 216, 264, 288, 312, 336, 360, 384, 432, 456, 504, 672, 840, 1008, 1176, and 1320 hours postdose

Population: Per protocol population includes all participants who complied with the protocol, had received MK-8189 treatment in Period 1 and MK-5720 treatment in Period 2, and had data available. Per protocol, placebo arms were not included in any PK outcome analyses. Panels C, D, E, and F were not enrolled, and no data was collected for this outcome measure.

Cmax is defined as the maximum concentration of MK-8189 (a metabolite of MK-5720) reached. Blood samples were collected at specified intervals for the determination of Cmax for MK-8198 following a single dose administration of MK-5720 in Period 2. Per protocol, this outcome measure has been reported by panel and dose.

Outcome measures

Outcome measures
Measure	Panel A: Period 1 MK-8189 4 mg n=6 Participants Participants received 7 days of oral MK-8189 4 mg (Period 1), followed by a single intramuscular (IM) injection of MK-5720 35 mg (Period 2).	Panel B: Period 1 MK-8189 8 mg n=6 Participants Participants received 7 days of oral MK-8189 8 mg (Period 1), followed by a single IM injection of MK-5720 70 mg (Period 2).	Placebo Period 1 Participants received 7 days of oral MK-8189 dose-matched placebo treatment (Period 1), followed by a single intramuscular (IM) injection of MK-5720 dose-matched placebo treatment (Period 2).	Panel C: Period 1 MK-8189 16 mg Participants received 7 days of oral MK-8189 16 mg (Period 1), followed by a single IM injection of MK-5720 140 mg (Period 2). No participants were enrolled into this arm.	Panel D: Period 1 MK-8189 24 mg Participants received 7 days of oral MK-8189 24 mg (Period 1), followed by a single IM injection of MK-5720 280 mg (Period 2). No participants were enrolled into this arm.	Panel E: Period 1 MK-8189 48 mg Participants received 7 days of oral MK-8189 48 mg (Period 1), followed by a single IM injection of MK-5720 560 mg (Period 2). No participants were enrolled into this arm.	Panel F: Period 1 MK-8189 48 mg Participants received 7 days of oral MK-8189 48 mg (Period 1), followed by a single IM injection of MK-5720 560 mg (Period 2), after a Pharmacokinetic (PK) break following Panel E. No participants were enrolled into this arm.	Panels C, D, E, and F: Placebo Period 1 Participants received 7 days of oral MK-8189 dose-matched placebo treatment (Period 1), followed by a single intramuscular (IM) injection of MK-5720 dose-matched placebo (Period 2). No participants were enrolled into this arm.
Cmax of MK-8189	18.8 nM Geometric Coefficient of Variation 569.7	104 nM Geometric Coefficient of Variation 90.1	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Predose, 0.5, 1, 2, 4, 6, 24, 48, 96, 120, 144, 168, 192, 216, 264, 288, 312, 336, 360, 384, 432, 456, 504, 672, 840, 1008, 1176, and 1320 hours postdose

Population: Per protocol population includes all participants who complied with the protocol, had received MK-8189 treatment in Period 1 and MK-5720 treatment in Period 2, and had data available. Per protocol, placebo arms were not included in any PK outcome analyses. Panels C, D, E, and F were not enrolled, and no data was collected for this outcome measure.

Tmax is defined as the time to maximum concentration of MK-8189 (a metabolite of MK-5720). Blood samples were collected at specified intervals for the determination of Tmax for MK-8198 following a single dose administration of MK-5720 in Period 2. Per protocol, this outcome measure has been reported by panel and dose.

Outcome measures

Outcome measures
Measure	Panel A: Period 1 MK-8189 4 mg n=6 Participants Participants received 7 days of oral MK-8189 4 mg (Period 1), followed by a single intramuscular (IM) injection of MK-5720 35 mg (Period 2).	Panel B: Period 1 MK-8189 8 mg n=6 Participants Participants received 7 days of oral MK-8189 8 mg (Period 1), followed by a single IM injection of MK-5720 70 mg (Period 2).	Placebo Period 1 Participants received 7 days of oral MK-8189 dose-matched placebo treatment (Period 1), followed by a single intramuscular (IM) injection of MK-5720 dose-matched placebo treatment (Period 2).	Panel C: Period 1 MK-8189 16 mg Participants received 7 days of oral MK-8189 16 mg (Period 1), followed by a single IM injection of MK-5720 140 mg (Period 2). No participants were enrolled into this arm.	Panel D: Period 1 MK-8189 24 mg Participants received 7 days of oral MK-8189 24 mg (Period 1), followed by a single IM injection of MK-5720 280 mg (Period 2). No participants were enrolled into this arm.	Panel E: Period 1 MK-8189 48 mg Participants received 7 days of oral MK-8189 48 mg (Period 1), followed by a single IM injection of MK-5720 560 mg (Period 2). No participants were enrolled into this arm.	Panel F: Period 1 MK-8189 48 mg Participants received 7 days of oral MK-8189 48 mg (Period 1), followed by a single IM injection of MK-5720 560 mg (Period 2), after a Pharmacokinetic (PK) break following Panel E. No participants were enrolled into this arm.	Panels C, D, E, and F: Placebo Period 1 Participants received 7 days of oral MK-8189 dose-matched placebo treatment (Period 1), followed by a single intramuscular (IM) injection of MK-5720 dose-matched placebo (Period 2). No participants were enrolled into this arm.
Tmax of MK-8189	96.00 hr Interval 24.0 to 504.0	120.00 hr Interval 96.0 to 288.0	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Predose, 0.5, 1, 2, 4, 6, 24, 48, 96, 120, 144, 168, 192, 216, 264, 288, 312, 336, 360, 384, 432, 456, 504, and 672 hours postdose

Population: Per protocol population includes all participants who complied with the protocol, had received MK-8189 treatment in Period 1 and MK-5720 treatment in Period 2, and had data available. Per protocol, placebo arms were not included in any PK outcome analyses. Panels C, D, E, and F were not enrolled, and no data was collected for this outcome measure.

C28d is defined as the maximum concentration from time zero to 28 days of MK-8189 (a metabolite of MK-5720). Blood samples were collected at specified intervals for the determination of C28d for MK-8198 following a single dose administration of MK-5720 in Period 2. Per protocol, this outcome measure has been reported by panel and dose. In cases where C28d values were below the limit of quantitation, geometric mean was not calculable and indicated as "NA."

Outcome measures

Outcome measures
Measure	Panel A: Period 1 MK-8189 4 mg n=6 Participants Participants received 7 days of oral MK-8189 4 mg (Period 1), followed by a single intramuscular (IM) injection of MK-5720 35 mg (Period 2).	Panel B: Period 1 MK-8189 8 mg n=6 Participants Participants received 7 days of oral MK-8189 8 mg (Period 1), followed by a single IM injection of MK-5720 70 mg (Period 2).	Placebo Period 1 Participants received 7 days of oral MK-8189 dose-matched placebo treatment (Period 1), followed by a single intramuscular (IM) injection of MK-5720 dose-matched placebo treatment (Period 2).	Panel C: Period 1 MK-8189 16 mg Participants received 7 days of oral MK-8189 16 mg (Period 1), followed by a single IM injection of MK-5720 140 mg (Period 2). No participants were enrolled into this arm.	Panel D: Period 1 MK-8189 24 mg Participants received 7 days of oral MK-8189 24 mg (Period 1), followed by a single IM injection of MK-5720 280 mg (Period 2). No participants were enrolled into this arm.	Panel E: Period 1 MK-8189 48 mg Participants received 7 days of oral MK-8189 48 mg (Period 1), followed by a single IM injection of MK-5720 560 mg (Period 2). No participants were enrolled into this arm.	Panel F: Period 1 MK-8189 48 mg Participants received 7 days of oral MK-8189 48 mg (Period 1), followed by a single IM injection of MK-5720 560 mg (Period 2), after a Pharmacokinetic (PK) break following Panel E. No participants were enrolled into this arm.	Panels C, D, E, and F: Placebo Period 1 Participants received 7 days of oral MK-8189 dose-matched placebo treatment (Period 1), followed by a single intramuscular (IM) injection of MK-5720 dose-matched placebo (Period 2). No participants were enrolled into this arm.
Concentration at Day 28 (C28d) of MK-8189	NA nM Geometric Coefficient of Variation NA NA = Geometric mean (% GCV) were not calculable as plasma concentrations were the below the limit of quantitation.	2.96 nM Geometric Coefficient of Variation 693.7	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Predose, 0.5, 1, 2, 4, 6, 24, 48, 96, 120, 144, 168, 192, 216, 264, 288, 312, 336, 360, 384, 432, 456, 504, 672, 840, 1008, 1176, and 1320 hours postdose

Population: Per protocol population includes all participants who complied with the protocol, had received MK-8189 treatment in Period 1 and MK-5720 treatment in Period 2, and had data available. Per protocol, placebo arms were not included in any PK outcome analyses. Panels C, D, E, and F were not enrolled, and no data was collected for this outcome measure.

CL/F is the rate at which the MK-8189 (a metabolite of MK-5720) is completely removed from plasma. Blood samples were collected at specified intervals for the determination of CL/F for MK-8198 following a single dose administration of MK-5720 in Period 2. Per protocol, this outcome measure has been reported by panel and dose.

Outcome measures

Outcome measures
Measure	Panel A: Period 1 MK-8189 4 mg n=4 Participants Participants received 7 days of oral MK-8189 4 mg (Period 1), followed by a single intramuscular (IM) injection of MK-5720 35 mg (Period 2).	Panel B: Period 1 MK-8189 8 mg n=6 Participants Participants received 7 days of oral MK-8189 8 mg (Period 1), followed by a single IM injection of MK-5720 70 mg (Period 2).	Placebo Period 1 Participants received 7 days of oral MK-8189 dose-matched placebo treatment (Period 1), followed by a single intramuscular (IM) injection of MK-5720 dose-matched placebo treatment (Period 2).	Panel C: Period 1 MK-8189 16 mg Participants received 7 days of oral MK-8189 16 mg (Period 1), followed by a single IM injection of MK-5720 140 mg (Period 2). No participants were enrolled into this arm.	Panel D: Period 1 MK-8189 24 mg Participants received 7 days of oral MK-8189 24 mg (Period 1), followed by a single IM injection of MK-5720 280 mg (Period 2). No participants were enrolled into this arm.	Panel E: Period 1 MK-8189 48 mg Participants received 7 days of oral MK-8189 48 mg (Period 1), followed by a single IM injection of MK-5720 560 mg (Period 2). No participants were enrolled into this arm.	Panel F: Period 1 MK-8189 48 mg Participants received 7 days of oral MK-8189 48 mg (Period 1), followed by a single IM injection of MK-5720 560 mg (Period 2), after a Pharmacokinetic (PK) break following Panel E. No participants were enrolled into this arm.	Panels C, D, E, and F: Placebo Period 1 Participants received 7 days of oral MK-8189 dose-matched placebo treatment (Period 1), followed by a single intramuscular (IM) injection of MK-5720 dose-matched placebo (Period 2). No participants were enrolled into this arm.
CL/F of MK-8189	7.43 Liters/hr Geometric Coefficient of Variation 75.3	3.92 Liters/hr Geometric Coefficient of Variation 93.9	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Predose, 0.5, 1, 2, 4, 6, 24, 48, 96, 120, 144, 168, 192, 216, 264, 288, 312, 336, 360, 384, 432, 456, 504, 672, 840, 1008, 1176, and 1320 hours postdose

Population: Per protocol population includes all participants who complied with the protocol, had received MK-8189 treatment in Period 1 and MK-5720 treatment in Period 2, and had data available. Per protocol, placebo arms were not included in any PK outcome analyses. Panels C, D, E, and F were not enrolled, and no data was collected for this outcome measure.

Vz/F is the apparent volume of distribution of MK-8189 (a metabolite of MK-5720). Blood samples were collected at specified intervals for the determination of Vz/F for MK-8198 following a single dose administration of MK-5720 in Period 2. Per protocol, this outcome measure has been reported by panel and dose.

Outcome measures

Outcome measures
Measure	Panel A: Period 1 MK-8189 4 mg n=4 Participants Participants received 7 days of oral MK-8189 4 mg (Period 1), followed by a single intramuscular (IM) injection of MK-5720 35 mg (Period 2).	Panel B: Period 1 MK-8189 8 mg n=6 Participants Participants received 7 days of oral MK-8189 8 mg (Period 1), followed by a single IM injection of MK-5720 70 mg (Period 2).	Placebo Period 1 Participants received 7 days of oral MK-8189 dose-matched placebo treatment (Period 1), followed by a single intramuscular (IM) injection of MK-5720 dose-matched placebo treatment (Period 2).	Panel C: Period 1 MK-8189 16 mg Participants received 7 days of oral MK-8189 16 mg (Period 1), followed by a single IM injection of MK-5720 140 mg (Period 2). No participants were enrolled into this arm.	Panel D: Period 1 MK-8189 24 mg Participants received 7 days of oral MK-8189 24 mg (Period 1), followed by a single IM injection of MK-5720 280 mg (Period 2). No participants were enrolled into this arm.	Panel E: Period 1 MK-8189 48 mg Participants received 7 days of oral MK-8189 48 mg (Period 1), followed by a single IM injection of MK-5720 560 mg (Period 2). No participants were enrolled into this arm.	Panel F: Period 1 MK-8189 48 mg Participants received 7 days of oral MK-8189 48 mg (Period 1), followed by a single IM injection of MK-5720 560 mg (Period 2), after a Pharmacokinetic (PK) break following Panel E. No participants were enrolled into this arm.	Panels C, D, E, and F: Placebo Period 1 Participants received 7 days of oral MK-8189 dose-matched placebo treatment (Period 1), followed by a single intramuscular (IM) injection of MK-5720 dose-matched placebo (Period 2). No participants were enrolled into this arm.
Vz/F of MK-8189	697 Liters Geometric Coefficient of Variation 97.0	593 Liters Geometric Coefficient of Variation 126.7	—	—	—	—	—	—

PRIMARY outcome

Timeframe: Predose, 0.5, 1, 2, 4, 6, 24, 48, 96, 120, 144, 168, 192, 216, 264, 288, 312, 336, 360, 384, 432, 456, 504, 672, 840, 1008, 1176, and 1320 hours postdose

Population: Per protocol population includes all participants who complied with the protocol, had received MK-8189 treatment in Period 1 and MK-5720 treatment in Period 2, and had data available. Per protocol, placebo arms were not included in any PK outcome analyses. Panels C, D, E, and F were not enrolled, and no data was collected for this outcome measure.

t1/2 is defined as the time required to divide plasma concentration of MK-8189 (a metabolite of MK-5720) by half after reaching pseudo-equilibrium. Blood samples were collected at specified intervals for the determination of Half-life (t1/2) for MK-8198 following a single dose administration of MK-5720 in Period 2. Per protocol, this outcome measure has been reported by panel and dose.

Outcome measures

Outcome measures
Measure	Panel A: Period 1 MK-8189 4 mg n=4 Participants Participants received 7 days of oral MK-8189 4 mg (Period 1), followed by a single intramuscular (IM) injection of MK-5720 35 mg (Period 2).	Panel B: Period 1 MK-8189 8 mg n=6 Participants Participants received 7 days of oral MK-8189 8 mg (Period 1), followed by a single IM injection of MK-5720 70 mg (Period 2).	Placebo Period 1 Participants received 7 days of oral MK-8189 dose-matched placebo treatment (Period 1), followed by a single intramuscular (IM) injection of MK-5720 dose-matched placebo treatment (Period 2).	Panel C: Period 1 MK-8189 16 mg Participants received 7 days of oral MK-8189 16 mg (Period 1), followed by a single IM injection of MK-5720 140 mg (Period 2). No participants were enrolled into this arm.	Panel D: Period 1 MK-8189 24 mg Participants received 7 days of oral MK-8189 24 mg (Period 1), followed by a single IM injection of MK-5720 280 mg (Period 2). No participants were enrolled into this arm.	Panel E: Period 1 MK-8189 48 mg Participants received 7 days of oral MK-8189 48 mg (Period 1), followed by a single IM injection of MK-5720 560 mg (Period 2). No participants were enrolled into this arm.	Panel F: Period 1 MK-8189 48 mg Participants received 7 days of oral MK-8189 48 mg (Period 1), followed by a single IM injection of MK-5720 560 mg (Period 2), after a Pharmacokinetic (PK) break following Panel E. No participants were enrolled into this arm.	Panels C, D, E, and F: Placebo Period 1 Participants received 7 days of oral MK-8189 dose-matched placebo treatment (Period 1), followed by a single intramuscular (IM) injection of MK-5720 dose-matched placebo (Period 2). No participants were enrolled into this arm.
t1/2 of MK-8189	65.0 hr Geometric Coefficient of Variation 62.5	105 hr Geometric Coefficient of Variation 71.3	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Predose, 0.5, 1, 2, 4, 6, 24, 48, 96, 120, 144, 168, 192, 216, 264, 288, 312, 336, 360, 384, 432, 456, 504, and 672 postdose

Population: Per protocol, this outcome measure is specific for Panels D, E, and F only. Panels C, D, E and F were not enrolled, and no data was collected for this outcome measure. Per protocol, placebo arms were not included in any PK outcome analyses.

C28d tied to specific exposures of MK-8189 is defined as the maximum concentration from time zero to 28 days of MK-8189 tied to specific exposures. Blood samples were collected at specified intervals for the determination of C28d tied to specific exposures of MK-8189 (metabolite of MK-5720) following a single dose administration of MK-5720 in Period 2. Per protocol, this outcome measure is specific for Panels D, E, and F only. Panels C, D, E and F were not enrolled, and no data was collected for this outcome measure.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Predose, 0.5, 1, 2, 4, 6, 24, 48, 96, 120, 144, 168, 192, 216, 264, 288, 312, 336, 360, 384, 432, 456, 504, and 672 hours postdose

Population: Per protocol, this outcome measure is specific for Panels C, D, E, and F, and data was not planned or collected for Panels A and B. Per protocol, placebo arms were not included in any PK outcome analyses. Panels C, D, E, and F were not enrolled, and no data was collected for this outcome measure.

Blood samples were to be collected at specified intervals for the determination of AUC0-28 of MK-8189 (a metabolite of MK-5720) after administration of MK-5720 (Period 2) in the gluteal muscle and deltoid muscle. AUC0-28 is defined as the area under the plasma concentration-time curve from time zero to 28 days of MK-8189. Per protocol, this outcome measure is specific for Panels C, D, E, and F, and data was not planned or collected for Panels A or B. Panels C, D, E, and F were not enrolled, and no data was collected for this outcome measure.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Predose, 0.5, 1, 2, 4, 6, 24, 48, 96, 120, 144, 168, 192, 216, 264, 288, 312, 336, 360, 384, 432, 456, 504, 672, 840, 1008, 1176, and 1320 hours postdose

Population: Per protocol, this outcome measure is specific for Panels C, D, E, and F, and data was not planned or collected for Panels A and B. Per protocol, placebo arms were not included in any PK outcome analyses. Panels C, D, E, and F were not enrolled, and no data was collected for this outcome measure.

Blood samples were to be collected at specified intervals for the determination of AUC-inf of MK-8189 (a metabolite of MK-5720) after administration of MK-5720 (Period 2) in the gluteal muscle and deltoid muscle. AUC0-inf is defined as the area under concentration-time curve from time zero to infinity of MK-8189. Per protocol, this outcome measure is specific for Panels C, D, E, and F, and data was not planned or collected for Panels A or B. Panels C, D, E, and F were not enrolled, and no data was collected for this outcome measure.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Predose, 0.5, 1, 2, 4, 6, 24, 48, 96, 120, 144, 168, 192, 216, 264, 288, 312, 336, 360, 384, 432, 456, 504, 672, 840, 1008, 1176, and 1320 hours postdose

Population: Per protocol, this outcome measure is specific for Panels C, D, E, and F, and data was not planned or collected for Panels A and B. Per protocol, placebo arms were not included in any PK outcome analyses. Panels C, D, E, and F were not enrolled, and no data was collected for this outcome measure.

Blood samples were to be collected at specified intervals for the determination of Cmax of MK-8189 (a metabolite of MK-5720) after administration of MK-5720 (Period 2) in the gluteal muscle and deltoid muscle. Cmax is defined as the maximum concentration of MK-8189. Per protocol, this outcome measure is specific for Panels C, D, E, and F, and data was not planned or collected for Panels A or B. Panels C, D, E, and F were not enrolled, and no data was collected for this outcome measure.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Predose, 0.5, 1, 2, 4, 6, 24, 48, 96, 120, 144, 168, 192, 216, 264, 288, 312, 336, 360, 384, 432, 456, 504, 672, 840, 1008, 1176, 1320 hours postdose

Population: Per protocol, this outcome measure is specific for Panels C, D, E, and F, and data was not planned or collected for Panels A and B. Per protocol, placebo arms were not included in any PK outcome analyses. Panels C, D, E, and F were not enrolled, and no data was collected for this outcome measure.

Blood samples were to be collected at specified intervals for determination of Tmax of MK-8189 (a metabolite of MK-5720) after administration of MK-5720 (Period 2) in the gluteal muscle and deltoid muscle. Tmax is defined as the time to maximum concentration of MK-8189. Per protocol, this outcome measure is specific for Panels C, D, E, and F, and data was not planned or collected for Panels A or B. Panels C, D, E, and F were not enrolled, and no data was collected for this outcome measure.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Predose, 0.5, 1, 2, 4, 6, 24, 48, 96, 120, 144, 168, 192, 216, 264, 288, 312, 336, 360, 384, 432, 456, 504, and 672 hours postdose

Population: Per protocol, this outcome measure is specific for Panels C, D, E, and F, and data was not planned or collected for Panels A and B. Per protocol, placebo arms were not included in any PK outcome analyses. Panels C, D, E, and F were not enrolled, and no data was collected for this outcome measure.

Blood samples were to be collected at specified intervals for the determination of C28d of MK-8189 (a metabolite of MK-5720) after administration of MK-5720 (Period 2) in the gluteal muscle and deltoid muscle. C28d is defined as the maximum concentration from time zero to 28 days of MK-8189. Per protocol, this outcome measure is specific for Panels C, D, E, and F, and data was not planned or collected for Panels A or B. Panels C, D, E, and F were not enrolled, and no data was collected for this outcome measure.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Predose, 0.5, 1, 2, 4, 6, 24, 48, 96, 120, 144, 168, 192, 216, 264, 288, 312, 336, 360, 384, 432, 456, 504, 672, 840, 1008, 1176, and 1320 hours postdose

Population: Per protocol, this outcome measure is specific for Panels C, D, E, and F, and data was not planned or collected for Panels A and B. Per protocol, placebo arms were not included in any PK outcome analyses. Panels C, D, E, and F were not enrolled, and no data was collected for this outcome measure.

Blood samples were to be collected at specified intervals for the determination of CL/F of MK-8189 (a metabolite of MK-5720) after administration of MK-5720 (Period 2) in the gluteal muscle and deltoid muscle. CL/F is the rate at which the MK-8189 is completely removed from plasma. Per protocol, this outcome measure is specific for Panels C, D, E, and F, and data was not planned or collected for Panels A or B. Panels C, D, E, and F were not enrolled, and no data was collected for this outcome measure.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Predose, 0.5, 1, 2, 4, 6, 24, 48, 96, 120, 144, 168, 192, 216, 264, 288, 312, 336, 360, 384, 432, 456, 504, 672, 840, 1008, 1176, and 1320 hours postdose

Population: Per protocol, this outcome measure is specific for Panels C, D, E, and F, and data was not planned or collected for Panels A and B. Per protocol, placebo arms were not included in any PK outcome analyses. Panels C, D, E, and F were not enrolled, and no data was collected for this outcome measure.

Blood samples were to be collected at specified intervals for the determination of distribution of MK-8189 (metabolite of MK-5720) after administration of MK-5720 (Period 2) in the gluteal muscle versus deltoid muscle. Vz/F is the apparent volume of distribution of MK-8189. Per protocol, this outcome measure is specific for Panels C, D, E, and F, and data was not planned or collected for Panels A or B. Panels C, D, E, and F were not enrolled, and no data was collected for this outcome measure.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Predose, 0.5, 1, 2, 4, 6, 24, 48, 96, 120, 144, 168, 192, 216, 264, 288, 312, 336, 360, 384, 432, 456, 504, 672, 840, 1008, 1176, and 1320 hours postdose

Population: Per protocol, this outcome measure is specific for Panels C, D, E, and F, and data was not planned or collected for Panels A and B. Per protocol, placebo arms were not included in any PK outcome analyses. Panels C, D, E, and F were not enrolled, and no data was collected for this outcome measure.

Blood samples were to be collected at specified intervals for the determination of t1/2 of MK-8189 (metabolite of MK-5720) after administration of MK-5720 (Period 2) in the gluteal muscle and deltoid muscle. t1/2 is defined as the time required divide plasma concentration of MK-8189 (metabolite of MK-5720) by half after reaching pseudo-equilibrium. Per protocol, this outcome measure is specific for Panels C, D, E, and F, and data was not planned or collected for Panels A or B. Panels C, D, E, and F were not enrolled, and no data was collected for this outcome measure.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Predose, 0.5, 1, 2, 4, 6, 24, 48, 96, 120, 144, 168, 192, 216, 264, 288, 312, 336, 360, 384, 432, 456, 504, 672, 840, 1008, 1176, and 1320 hours postdose

Population: Per protocol, this outcome measure is specific for Panels C, D, E, and F, and data was not planned or collected for Panels A and B. Per protocol, placebo arms were not included in any PK outcome analyses. Panels C, D, E, and F were not enrolled, and no data was collected for this outcome measure.

Blood samples were to be collected at specified intervals for the determination of AUC0-last after administration of MK-5720 (Period 2) in the gluteal muscle and deltoid muscle. AUC0-last is defined as the area under the concentration-time curve from time zero to time of last measurable concentration of MK-5720. Per protocol, this outcome measure is specific for Panels C, D, E, and F, and data was not planned or collected for Panels A or B. Panels C, D, E, and F were not enrolled, and no data was collected for this outcome measure.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Predose, 0.5, 1, 2, 4, 6, 24, 48, 96, 120, 144, 168, 192, 216, 264, 288, 312, 336, 360, 384, 432, 456, 504, 672, 840, 1008, 1176, and 1320 hours postdose

Population: Per protocol, this outcome measure is specific for Panels C, D, E, and F, and data was not planned or collected for Panels A and B. Per protocol, placebo arms were not included in any PK outcome analyses. Panels C, D, E, and F were not enrolled, and no data was collected for this outcome measure.

Blood samples were to be collected at specified intervals for the determination of AUC-inf after administration of MK-5720 (Period 2) in the gluteal muscle and deltoid muscle. AUC0-inf is defined as the area under concentration-time curve from time zero to infinity. Per protocol, this outcome measure is specific for Panels C, D, E, and F, and data was not planned or collected for Panels A or B. Panels C, D, E, and F were not enrolled, and no data was collected for this outcome measure.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Predose, 0.5, 1, 2, 4, 6, 24, 48, 96, 120, 144, 168, 192, 216, 264, 288, 312, 336, 360, 384, 432, 456, 504, 672, 840, 1008, 1176, and 1320 hours postdose

Population: Per protocol, this outcome measure is specific for Panels C, D, E, and F, and data was not planned or collected for Panels A and B. Per protocol, placebo arms were not included in any PK outcome analyses. Panels C, D, E, and F were not enrolled, and no data was collected for this outcome measure.

Blood samples were to be collected at specified intervals for the determination of Cmax after administration of MK-5720 (Period 2) in the gluteal muscle and deltoid muscle. Cmax is defined as the maximum concentration of MK-5720 reached. Per protocol, this outcome measure is specific for Panels C, D, E, and F, and data was not planned or collected for Panels A or B. Panels C, D, E, and F were not enrolled, and no data was collected for this outcome measure.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Predose, 0.5, 1, 2, 4, 6, 24, 48, 96, 120, 144, 168, 192, 216, 264, 288, 312, 336, 360, 384, 432, 456, 504, 672, 840, 1008, 1176, and 1320 hours postdose

Population: Per protocol, this outcome measure is specific for Panels C, D, E, and F, and data was not planned or collected for Panels A and B. Per protocol, placebo arms were not included in any PK outcome analyses. Panels C, D, E, and F were not enrolled, and no data was collected for this outcome measure.

Blood samples were to be collected at specified intervals for the determination of Tmax after administration of MK-5720 (Period 2) in the gluteal muscle and deltoid muscle. Tmax is defined as the time to maximum concentration of MK-5720 reached. Per protocol, this outcome measure is specific for Panels C, D, E, and F, and data was not planned or collected for Panels A or B. Panels C, D, E, and F were not enrolled, and no data was collected for this outcome measure.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Predose, 0.5, 1, 2, 4, 6, 24, 48, 96, 120, 144, 168, 192, 216, 264, 288, 312, 336, 360, 384, 432, 456, 504, 672, 840, 1008, 1176, and 1320 hours postdose

Population: Per protocol, this outcome measure is specific for Panels C, D, E, and F, and data was not planned or collected for Panels A and B. Per protocol, placebo arms were not included in any PK outcome analyses. Panels C, D, E, and F were not enrolled, and no data was collected for this outcome measure.

Blood samples were to be collected at specified intervals for the determination of CL/F after administration of MK-5720 (Period 2) in the gluteal muscle and deltoid muscle. CL/F is the rate at which the MK-5720 is completely removed from plasma. Per protocol, this outcome measure is specific for Panels C, D, E, and F, and data was not planned or collected for Panels A or B. Panels C, D, E, and F were not enrolled, and no data was collected for this outcome measure.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Predose, 0.5, 1, 2, 4, 6, 24, 48, 96, 120, 144, 168, 192, 216, 264, 288, 312, 336, 360, 384, 432, 456, 504, 672, 840, 1008, 1176, and 1320 hours postdose

Population: Per protocol, this outcome measure is specific for Panels C, D, E, and F, and data was not planned or collected for Panels A and B. Per protocol, placebo arms were not included in any PK outcome analyses. Panels C, D, E, and F were not enrolled, and no data was collected for this outcome measure.

Blood samples were to be collected at specified intervals for the determination Vz/F after administration of MK-5720 (Period 2) in the gluteal muscle and deltoid muscle. Vz/F is the apparent volume of distribution of MK-5720. Per protocol, this outcome measure is specific for Panels C, D, E, and F, and data was not planned or collected for Panels A or B. Panels C, D, E, and F were not enrolled, and no data was collected for this outcome measure.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Predose, 0.5, 1, 2, 4, 6, 24, 48, 96, 120, 144, 168, 192, 216, 264, 288, 312, 336, 360, 384, 432, 456, 504, 672, 840, 1008, 1176, and 1320 hours postdose

Population: Per protocol, this outcome measure is specific for Panels C, D, E, and F, and data was not planned or collected for Panels A and B. Per protocol, placebo arms were not included in any PK outcome analyses. Panels C, D, E, and F were not enrolled, and no data was collected for this outcome measure.

Blood samples were to be collected at specified intervals for the determination t1/2 after administration of MK-5720 (Period 2) in the gluteal muscle and deltoid muscle. t1/2 is defined as the time required to divide plasma concentration of MK-5720 by half after reaching pseudo-equilibrium. Per protocol, this outcome measure is specific for Panels C, D, E, and F, and data was not planned or collected for Panels A or B. Panels C, D, E, and F were not enrolled, and no data was collected for this outcome measure.

Outcome measures

Outcome data not reported

Adverse Events

Panel A: Period 1 MK-8189 4 mg

Serious events: 0 serious events

Other events: 1 other events

Deaths: 0 deaths

Panel B: Period 1 MK-8189 8 mg

Serious events: 0 serious events

Other events: 4 other events

Deaths: 0 deaths

Placebo Period 1

Serious events: 0 serious events

Other events: 2 other events

Deaths: 0 deaths

Panel A: Period 2 MK-5720 35mg

Serious events: 0 serious events

Other events: 1 other events

Deaths: 0 deaths

Panel B: Period 2 MK-5720 70 mg

Serious events: 0 serious events

Other events: 2 other events

Deaths: 0 deaths

Placebo Period 2

Serious events: 0 serious events

Other events: 1 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure	Panel A: Period 1 MK-8189 4 mg n=6 participants at risk Participants received 7 days of oral MK-8189 4 mg (Period 1), followed by a single intramuscular (IM) injection of MK-5720 35 mg (Period 2).	Panel B: Period 1 MK-8189 8 mg n=7 participants at risk Participants received 7 days of oral MK-8189 8 mg (Period 1), followed by a single IM injection of MK-5720 70 mg (Period 2).	Placebo Period 1 n=4 participants at risk Participants received 7 days of oral MK-8189 dose-matched placebo treatment (Period 1), followed by a single intramuscular (IM) injection of MK-5720 dose-matched placebo treatment (Period 2).	Panel A: Period 2 MK-5720 35mg n=6 participants at risk Participants received 7 days of oral MK-8189 4 mg (Period 1), followed by a single intramuscular (IM) injection of MK-5720 35 mg (Period 2).	Panel B: Period 2 MK-5720 70 mg n=6 participants at risk Participants received 7 days of oral MK-8189 8 mg (Period 1), followed by a single IM injection of MK-5720 70 mg (Period 2).	Placebo Period 2 n=4 participants at risk Participants received 7 days of oral MK-8189 dose-matched placebo treatment (Period 1), followed by a single intramuscular (IM) injection of MK-5720 dose-matched placebo treatment (Period 2).
Cardiac disorders Tachycardia	0.00% 0/6 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.	14.3% 1/7 • Number of events 1 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.	0.00% 0/4 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.	0.00% 0/6 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.	0.00% 0/6 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.	0.00% 0/4 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.
Gastrointestinal disorders Constipation	0.00% 0/6 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.	0.00% 0/7 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.	0.00% 0/4 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.	16.7% 1/6 • Number of events 1 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.	0.00% 0/6 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.	0.00% 0/4 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.
General disorders Pain	0.00% 0/6 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.	0.00% 0/7 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.	0.00% 0/4 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.	0.00% 0/6 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.	16.7% 1/6 • Number of events 1 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.	0.00% 0/4 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.
Infections and infestations Folliculitis	0.00% 0/6 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.	0.00% 0/7 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.	0.00% 0/4 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.	0.00% 0/6 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.	16.7% 1/6 • Number of events 1 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.	0.00% 0/4 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.
Infections and infestations Influenza	16.7% 1/6 • Number of events 1 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.	0.00% 0/7 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.	0.00% 0/4 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.	0.00% 0/6 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.	0.00% 0/6 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.	0.00% 0/4 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.
Musculoskeletal and connective tissue disorders Back pain	0.00% 0/6 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.	14.3% 1/7 • Number of events 1 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.	0.00% 0/4 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.	0.00% 0/6 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.	16.7% 1/6 • Number of events 1 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.	0.00% 0/4 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.
Musculoskeletal and connective tissue disorders Flank pain	0.00% 0/6 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.	0.00% 0/7 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.	25.0% 1/4 • Number of events 1 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.	0.00% 0/6 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.	0.00% 0/6 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.	0.00% 0/4 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.
Nervous system disorders Akathisia	0.00% 0/6 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.	14.3% 1/7 • Number of events 1 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.	0.00% 0/4 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.	0.00% 0/6 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.	0.00% 0/6 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.	0.00% 0/4 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.
Nervous system disorders Headache	0.00% 0/6 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.	14.3% 1/7 • Number of events 1 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.	0.00% 0/4 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.	0.00% 0/6 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.	0.00% 0/6 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.	0.00% 0/4 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.
Psychiatric disorders Abnormal dreams	0.00% 0/6 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.	0.00% 0/7 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.	25.0% 1/4 • Number of events 1 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.	0.00% 0/6 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.	0.00% 0/6 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.	0.00% 0/4 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.
Psychiatric disorders Agitation	0.00% 0/6 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.	14.3% 1/7 • Number of events 1 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.	0.00% 0/4 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.	0.00% 0/6 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.	0.00% 0/6 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.	0.00% 0/4 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.
Respiratory, thoracic and mediastinal disorders Cough	0.00% 0/6 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.	0.00% 0/7 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.	0.00% 0/4 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.	0.00% 0/6 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.	0.00% 0/6 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.	25.0% 1/4 • Number of events 1 • Up to approximately 82 days Population for All-cause mortality was All Randomized Participants. Population for non-serious adverse events and serious adverse events consists of all randomized participants who received at least 1 dose of the study intervention and have provided safety data at any time during the study. Panels C, D, E, and F were not enrolled, and no data was collected for these panels.

Additional Information

Senior Vice President, Global Clinical Development

Merck Sharp & Dohme LLC

Phone: 1-800-672-6372

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee If publication activity is not directed by the Sponsor, the investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments
Publication restrictions are in place

Restriction type: OTHER